Mesna
CNS Lymphoma
Samsung Medical CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the CNS Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Juan P. Alderuccio, MD | Phase 4 | BB |
(+)-VINCRISTINE Ruijin Hospital | Phase 4 | BB |
Cyclophosphamide Juan P. Alderuccio, MD | Phase 4 | BB |
Ifosfamide Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | BB |
PREDNISONE TABLETS Juan P. Alderuccio, MD | Phase 2 | B |
View all 20 →
Same molecule, other indications
Mesna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →